Digital Health Investment Weekly Report Vol.165 Highlights Major Funding Rounds and Industry Developments

Due to recent changes in the official account's push mechanism, we welcome you to set Boom Health as a “Star” on the homepage of our official account to receive the latest trends and expert insights in the digital healthcare industry at the earliest opportunity!

01 Overview of Global Digital Health Investment and Financing

Brain-Computer Interface Developer Neuralink Secures $600 Million in Funding

On May 27, brain-computer interface (BCI) system developer Neuralink secured $600 million in financing. This round of funding will continue to advance the development of its BCI technology, with plans to initiate clinical trials in 2026, aiming to restore vision in individuals with complete blindness.

Salvia BioElectronics, a developer of bioelectronic devices, secures $60 million in Series B financing

On May 27, bioelectronic device developer Salvia BioElectronics secured $60 million in Series B financing, led by Innovation Industries, with participation from Invest-NL, EIC Fund, Inkef, Panakès Partners, and others. The funds will primarily be used to complete clinical studies of its product, MySalvia, and to support subsequent commercialization efforts.

GeneMind, a Developer of Proprietary Gene Sequencing Instruments, Secures 280 Million Yuan in Series C+ Funding

On May 28, GeneMind, a developer of independently developed gene sequencing equipment, secured RMB 280 million in its Series C+ financing round. The round was jointly led by Sansure Biotech, KingMed Diagnostics, Shengwei Rongquan, and Jinhe Capital, with participation from institutions including Wujie Capital and Haikou Junxin. This financing will focus on two strategic goals: building a commercialization ecosystem and expanding global presence. It will provide ample momentum to strengthen market position, expand production capacity, and ensure regulatory compliance, thereby accelerating the dual breakthroughs of domestic substitution and the international expansion of Chinese technologies.

In Vitro Diagnostic Product Developer Pillar Biosciences Secures $34.5 Million in Funding

On May 27, in vitro diagnostics product developer Pillar Biosciences secured $34.5 million in financing, with strategic investment from Illumina, structured financing from Soleus Capital, and participation from existing investors. The funding will be used to drive Pillar’s commercial activities, including expanding its workforce and infrastructure to support biopharmaceutical partnerships and broaden the adoption of its distributable clinical test kits.

Oral Medical Polymer Materials Developer Polly New Materials Secures Over RMB 200 Million in Series B Financing

On May 27, Suzhou Polly Polymer Technology Co., Ltd., a developer of dental medical polymer materials, secured over RMB 200 million in Series B financing. The round was led by Luzhou Aero Engine Group and Zhilai Investment, with participation from multiple strategic investors and additional investment from existing shareholders such as Oasis Capital. The funds will be used to accelerate the research and development and industrial application of mass production technologies for 3D printing, drive innovation in high-performance materials, and explore integrated development with AI and future technologies.

Chamlion Technology, a Full-Process Digital Dentistry Service Provider, Secures Nearly RMB 200 Million in Series B+ Financing

On May 27, Chenglian Technology, a full-process digital service provider for dentistry, secured nearly RMB 200 million in its Series B+ financing round, jointly led by Fortune Capital and GTJA Investment. Chenglian Technology is dedicated to achieving full-process digitalization in oral dentistry through next-generation technologies. Leveraging its independently developed 3D printing and digital design technologies, the company has established a new dental ecosystem centered on the digitalization of denture processing.

Swiss Diagnostic Company Hedera Dx Secures €15 Million in Series A Funding

On May 27, Swiss diagnostics company Hedera Dx secured €15 million in Series A financing, led by Vsquared Ventures, with participation from existing investors Helsana HealthInvest, Eyrir Venture Management, Inventure, and Top Harvest, and new investor Tesi, a Finnish venture capital firm. The funding will support the company’s ongoing commercial expansion and data infrastructure development.

Biomimetic Recombinant Protein Developer Juyuan Biology Secures Over RMB 100 Million in Financing

On May 26, Juyuan Biology, a developer of biomimetic recombinant protein products, secured over RMB 100 million in financing, with joint investment from SDIC Investment Promotion and Yuexiu Industrial Fund. The funds will support Juyuan Biology in strengthening its strategic layout in the field of biosynthesis, comprehensively enhancing its overall competitiveness as a global leading “intelligent manufacturing platform” for functional proteins in synthetic biology.

Medical Aesthetics Skincare R&D Firm Weiming Shiguang Secures Nearly RMB 100 Million in Strategic Financing Round

On May 23, Weiming Shiguang, a developer of medical aesthetic skincare products, secured nearly RMB 100 million in strategic financing, jointly invested by L'Oréal Group and Nice Group. Weiming Shiguang has officially entered into a strategic partnership with L'Oréal Group to jointly promote sustainable beauty solutions and the application of cutting-edge technologies, leveraging Weiming Shiguang's plant callus tissue technology and AI-driven R&D platform.

Intelligent Vision Device Developer Pingfanghe Secures Nearly RMB 100 Million in Series B+ Funding

On May 22, Pingfanghe, a developer of intelligent vision equipment, secured nearly RMB 100 million in Series B+ financing. This round was exclusively invested by the Beijing Advanced Manufacturing and Intelligent Equipment Industry Investment Fund. The funds will primarily be used for research and development, as well as for expanding and implementing new industry applications.

Life Sciences Instrumentation and Biopharmaceutical Equipment R&D Developer LeadHealth Secures Nearly 100 Million Yuan in Angel Funding

On May 22, LiDe Health, a developer of life science instruments and biopharmaceutical equipment, secured nearly RMB 100 million in angel financing. The round was led by Jiadao Capital, with participation from Qiji Investment, CAS Star, Juke Emerging Industry Venture Capital, Jianshi Capital, and Jiuzhou Xinnuo. The funds will be used to accelerate R&D, product industrialization, and market expansion, thereby driving innovation and development in the fields of AI-powered life science instruments and intelligent bio-manufacturing equipment.

Genomic Analysis Cloud Solution Provider SeqOne Genomics Secures €20 Million in Funding

On May 28, SeqOne Genomics, a provider of cloud-based genomic analysis solutions, secured €20 million in funding. The round was led by Supernova Invest, with participation from existing investors Elaia, Omnes, and Mérieux Equity Partners. The proceeds will be used to accelerate global expansion, speed up entry into the U.S. market, and pursue strategic acquisitions, further solidifying its technological leadership.

Axle Health, Developer of Scheduling and Workforce Management Software for the Home Healthcare Sector, Raises $10 Million in Series A Funding

On May 22, Axle Health, a developer of scheduling and workforce management software for the home healthcare sector, secured $10 million in Series A financing. The round was led by F-Prime, with participation from Y Combinator, Pear VC, and Lightbank. The funds will be used to further develop its AI-driven logistics platform, optimize the scheduling and management of home care services, improve patient care quality, and reduce operational costs.

Huishui Medical, a Provider of Visual Rehabilitation Products and Services, Secures RMB 50 Million in Financing

On May 23, Huishi Medical, a provider of visual rehabilitation products and services, secured RMB 50 million in financing, led by Guangzhou Yongxiu Investment Group. The funds will be used to accelerate the deployment of its product matrix across both home and medical scenarios, and to deepen its exclusive technical collaboration with U.S.-based HTS Company.

Portal Access, a Provider of Advanced Vascular Access Solutions for Oncology, Secures $7 Million in Series A Funding

On May 27, Portal Access, a provider of advanced vascular access solutions for oncology, secured $7 million in Series A financing, with participation from U.S. physician investors and a U.S. venture capital fund. The proceeds will support the FDA approval and limited market launch of its next-generation chemotherapy port, Flexi-Port™ SLF-TANL™.

Digital Health Platform Brooklyn Health, Which Measures Mental Health Status, Raises $6.5 Million in Seed Funding

On May 27, Brooklyn Health, a digital health platform for measuring psychological conditions, secured $6.5 million in seed funding, led by HealthX with participation from Metrodora Ventures, Story Ventures, and others. The funds will be used to enhance the precision of its AI-driven clinical trial endpoints and advance the development of its electronic Clinical Outcome Assessment (eCOA) solution, Willis.

Virtual Care Platform Operator WellTheory Secures $5 Million in Funding

On May 22, WellTheory, a virtual care platform operator, secured $5 million in funding, with participation from Samsung Next, Opal Ventures, and Up2 Fund, while existing investors Accel, OVO Fund, and BoxGroup continued their support. The funds will be used to accelerate the development of its AI-driven care platforms, Care Hub and Care Scribe, and to drive itsOn HireExpansion of the Primary Health and Wellness Plan Market.

AI Gut Health Monitoring Device Developer Throne Secures $4 Million in Seed Funding

On May 23, Throne, a developer of AI-powered gut health monitoring devices, secured $4 million in seed funding. The round was led by Katie Jacobs Stanton, founder of Moxxie Ventures, with participation from prominent investors such as former cycling champion Lance Armstrong. Throne’s AI-driven smart toilet device uses cameras and computer vision technology to analyze excrement, enabling real-time monitoring of users’ gut health. The product is scheduled for official market launch in early 2026.

Aptar Digital Health Partners with AstraZeneca, Licensing AI Algorithm for Chronic Kidney Disease Detection

On May 23, Aptar Digital Health entered into a licensing agreement with AstraZeneca to utilize AstraZeneca’s artificial intelligence (AI) algorithms for the detection of chronic kidney disease (CKD). This collaboration grants Aptar access to AstraZeneca’s AI-based screening technology, aiming to identify CKD patients more efficiently. AstraZeneca’s algorithm focuses on enhancing early detection of CKD, a condition that typically progresses without obvious symptoms and is often only discovered in its late stages. By integrating this technology, Aptar seeks to improve diagnostic capabilities and streamline the identification process for healthcare providers.

Wondfo Biotech and Tencent Health Partner to Drive the Development of Smart Healthcare

On May 21, Wondfo Biotech and Tencent Health formally signed a strategic cooperation agreement in Beijing, marking a new stage in the deep integration of both parties in the field of AI + healthcare. This collaboration will focus on areas such as “AI + Laboratory Diagnostics,” “AI + Marketing,” and “AI + Health Management,” jointly building an intelligent and precise in vitro diagnostics and health service system, and propelling the industry into a new era of “Smart Medicine and Smart Testing.”

AI Technology Researcher John Snow Labs Acquires WiseCube

On May 27, AI healthcare company John Snow Labs acquired WiseCube, a pioneer in biomedical knowledge graphs and AI-driven literature analysis. WiseCube specializes in unifying and analyzing disparate biomedical datasets to provide rapid, evidence-based answers to complex medical questions. This acquisition will enable John Snow Labs to enhance its products and services in key areas, including improving biomedical literature reviews, accelerating drug discovery, and refining hallucination detection in medical large language models (LLMs).

Coalesce Capital, a Private Equity Firm Focused on Investing in Human Capital-Driven and Technology-Enabled Service Companies, Acquires DAS Health

On May 27, Coalesce Capital, a private equity firm focused on investing in human capital-driven and technology-enabled service companies, acquired a majority stake in DAS Health Ventures, a provider of healthcare IT and commercial solutions. DAS Health delivers IT, cybersecurity, revenue cycle management, and commercial solutions to thousands of healthcare organizations across North America, aiming to streamline workflows, enhance productivity, and improve patient care. This new partnership with Coalesce Capital will drive DAS Health’s expansion through investments in technology, talent, and strategic acquisitions.

Integrated Geriatric Care Provider Valir PACE Acquires Cherry Blossom PACE

On May 23, comprehensive geriatric care provider Valir PACE acquired Cherry Blossom PACE, further expanding its high-quality elderly care services in Northern Virginia. As a recognized leader in the Program of All-Inclusive Care for the Elderly (PACE), Valir PACE’s strategic acquisition reinforces its commitment to delivering high-quality, comprehensive care to seniors in Northern Virginia. With over a decade of experience providing all-inclusive care services to the elderly, Valir PACE supports participants in maintaining their independence and quality of life.

Equum Medical, a Provider of Acute Telehealth Clinical Workforce Solutions, Acquires VeeOne Health’s Clinical Services Business

On May 22, Equum Medical, a provider of acute care telehealth clinical workforce solutions, acquired the clinical services business of VeeOne Health. This strategic acquisition includes VeeOne Health’s service lines in telepsychiatry, teleneurology, tele-infectious diseases (Tele-ID), telepulmonology, and tele-intensive care (Tele-ICU). The acquisition significantly expands Equum Medical’s comprehensive telehealth offerings and solidifies its market leadership in acute care telehealth. The combined entity will support physician service coverage for more than 200 hospitals and post-acute care facilities across China.

VBData/Arterial Orange Industry Think Tank/China Renaissance / BGI Win-Win / Rock Health / Mobile Health News / FierceHealth, etc.

Compiled by: Hou Zhancai, Huang Changjian‍‍‍

Share

Like

Click "Like"